医药生物行业半年度投资策略：创新引领医药行业新发展

东方财富证券2025-07-04

【投资要点】近年来，中国创新药在全球医药市场中的影响力显著提升，中国正在进行的临床试验数量持续上升。根据药智网统计数据，截至6 月4 日，2025 年我国国产创新药发生BD 交易近80 项，其中License out 项目近60 项，License in 项目近20 项目。从已公布金额数据的项目来看，License out 项目涉及金额512 亿美元。我国PD-（L）1/VEGF-（A）双抗迎来...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2548398360?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-04 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2548398360","market":"sh","top_or_hot":-1,"title":"医药生物行业半年度投资策略：创新引领医药行业新发展","media":"东方财富证券","content":"<div>\n<p>【投资要点】近年来，中国创新药在全球医药市场中的影响力显著提升，中国正在进行的临床试验数量持续上升。根据药智网统计数据，截至6 月4 日，2025 年我国国产创新药发生BD 交易近80 项，其中License out 项目近60 项，License in 项目近20 项目。从已公布金额数据的项目来看，License out 项目涉及金额512 亿美元。我国PD-（L）1/VEGF-（A）双抗迎来...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704183135a436c4f3&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医药生物行业半年度投资策略：创新引领医药行业新发展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医药生物行业半年度投资策略：创新引领医药行业新发展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-04 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704183135a436c4f3&s=b><strong>东方财富证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【投资要点】近年来，中国创新药在全球医药市场中的影响力显著提升，中国正在进行的临床试验数量持续上升。根据药智网统计数据，截至6 月4 日，2025 年我国国产创新药发生BD 交易近80 项，其中License out 项目近60 项，License in 项目近20 项目。从已公布金额数据的项目来看，License out 项目涉及金额512 亿美元。我国PD-（L）1/VEGF-（A）双抗迎来...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704183135a436c4f3&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704183135a436c4f3&s=b","article_id":"2548398360","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704183135a436c4f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2548398360","pubTimestamp":1751558400,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近年来，中国创新药在全球医药市场中的影响力显著提升，中国正在进行的临床试验数量持续上升。中国创新药审评审批在加快。我国头部医药企业研发投入较快增长，研发成果有望逐步落地。随着全球抗生素需求的增长，抗生素中间体行业也呈现出稳步发展的态势。药辅新规实施在即，利好龙头企业。CDMO 行业从“规模红利”向“技术溢价”转型，中国CDMO行业已经迈入了细分赛道的多线发展阶段。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"163118":"医药生物","600216":"浙江医药","BK0188":"融资融券","02359":"药明康德","000808.SH":"医药生物","01801":"信达生物","01177":"中国生物制药","01530":"三生制药","BK0028":"国家队","BK0239":"医药制造","BK0191":"维生素","03933":"联邦制药"},"translate_title":"Semi-annual investment strategy for the pharmaceutical and biological industry: innovation leads the new development of the pharmaceutical industry","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"163118":1,"600216":0.9,"02359":0.9,"01177":0.9,"000808.SH":1,"01530":0.9,"01801":0.9,"03933":0.9},"content_text":"【投资要点】近年来，中国创新药在全球医药市场中的影响力显著提升，中国正在进行的临床试验数量持续上升。根据药智网统计数据，截至6 月4 日，2025 年我国国产创新药发生BD 交易近80 项，其中License out 项目近60 项，License in 项目近20 项目。从已公布金额数据的项目来看，License out 项目涉及金额512 亿美元。我国PD-（L）1/VEGF-（A）双抗迎来高光时刻。据Market.us 数据，全球双抗药物市场规模预计2024-2033 年CAGR 将达到37.5%，至2033 年其市场规模将达到约1926 亿美元。中国创新药审评审批在加快。我国头部医药企业研发投入较快增长，研发成果有望逐步落地。7 月1 日，国家医保局、国家卫生健康委印发《支持创新药高质量发展的若干措施》，从五方面提出16 条举措，对创新药研发、准入、入院使用和商保多元支付等进行全链条支持。有望推进“丙类目录”增设商业健康保险创新药品目录。推动创新药加快进入定点医药机构。原料药在外贸领域展现了较强的抗跌韧性。随着全球抗生素需求的增长，抗生素中间体行业也呈现出稳步发展的态势。绿色生产技术升级成为趋势。随着新产能的释放，维生素产业仍将保持竞争整合态势。药辅新规实施在即，利好龙头企业。未来植物胶囊的需求有望持续提升。全球医药研发服务行业，尤其是具有全球新药研发生产服务能力的平台型公司，有望受益于全球新药研发投入的持续增长和外包率的不断提升。CDMO 行业从“规模红利”向“技术溢价”转型，中国CDMO行业已经迈入了细分赛道的多线发展阶段。头部企业保持营收增长的同时，不断优化生产工艺和经营效率，以及临床后期和商业化项目增长带来的产能效率不断提升，从而提高了整体的盈利能力。2025 年初至2025 年6 月20 日，医药生物指数（申万）上涨4.57%，跑赢沪深300 指数6.81 个百分点，行业涨跌幅排名第6。2025 年初至今，涨幅最大的子板块为化学制药，涨幅18.57%；涨幅最小的子板块为中药，跌幅5.81%。【配置建议】创新药建议关注三生制药、三生国健、联邦制药、信达生物、中国生物制药等；原辅料建议关注天宇股份、浙江医药、山河药辅、山东赫达等；医疗服务建议关注药明康德等；医疗器械建议关注联影医疗、惠泰医疗、迈瑞医疗、澳华内镜等。【风险提示】行业政策变化风险；原材料价格大幅波动风险；主要产品销售增长不达预期；研发进展不达预期。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548398360","isCrawlerRequest":true}